NYSE:CCChemours Stock Price, Forecast & News

Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CC shares have increased by 73.8% and is now trading at $18.53.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Chemours.

Chemours is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Chemours.

Chemours Co (NYSE:CC) announced its quarterly earnings results on Thursday, July, 30th. The specialty chemicals company reported $0.18 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.09 by $0.09. The specialty chemicals company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.08 billion. Chemours had a negative net margin of 2.28% and a positive return on equity of 47.31%.
View Chemours' earnings history.

Chemours announced a quarterly dividend on Wednesday, July 29th. Shareholders of record on Monday, August 17th will be given a dividend of $0.25 per share on Tuesday, September 15th. This represents a $1.00 annualized dividend and a yield of 5.40%. The ex-dividend date is Friday, August 14th.
View Chemours' dividend history.

11 analysts have issued 1-year price objectives for Chemours' shares. Their forecasts range from $8.00 to $21.00. On average, they expect Chemours' share price to reach $14.00 in the next twelve months. This suggests that the stock has a possible downside of 24.4%.
View analysts' price targets for Chemours.

Media headlines about CC stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemours earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave media coverage about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Chemours.

Some companies that are related to Chemours include ASAHI KASEI COR/ADR (AHKSY), Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), SHOWA DENKO KK/ADR (SHWDY), Balchem (BCPC), W. R. Grace & Co (GRA), Univar (UNVR), Ingevity (NGVT), Innospec (IOSP), Olin (OLN), PQ Group (PQG), GCP Applied Technologies (GCP) and Livent (LTHM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA) and Energy Transfer LP Unit (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by a variety of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.53%), M&T Bank Corp (0.40%), New York State Teachers Retirement System (0.16%), First Trust Advisors LP (0.10%), Heritage Investors Management Corp (0.08%) and Comerica Bank (0.06%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher.
View institutional ownership trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, DNB Asset Management AS, SG Americas Securities LLC, Raymond James Financial Services Advisors Inc., Dupont Capital Management Corp, M&T Bank Corp, Envestnet Asset Management Inc., and ARGA Investment Management LP.
View insider buying and selling activity for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Raymond James & Associates, State of Michigan Retirement System, DAVENPORT & Co LLC, Sigma Planning Corp, Cambridge Investment Research Advisors Inc., Sciencast Management LP, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher.
View insider buying and selling activity for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CC stock can currently be purchased for approximately $18.53.

Chemours has a market capitalization of $3.04 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

The official website for Chemours is www.chemours.com.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]